M&A / Deals Cancer biotech Parabilis books record IPO, raising $670m PharmaphorumParabilis has broken the IPO record set by Kailera in April, packing its coffers as it starts an ambitious trial programme for lead drug zolucatetide.OncologyRead full story pharminent June 10, 2026 (Last updated: June 10, 2026) Pharmaphorum Parabilis has broken the IPO record set by Kailera in April, packing its coffers as it starts an ambitious trial programme for lead drug zolucatetide. Oncology Read full story Post navigation Previous: Alzecure enters collaboration and with Lilly for Alzheimer’s projectNext: Aditxt and Ignite announce merger plans with strategic partner Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
